Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent GvHD. We are doing this study to see if a lower dose of cyclophosphamide after transplant is safer, but just as effective. Cyclophosphamide can prevent GvHD, but it can also make you sick and more likely to get an infection. This study will look at how well a lower dose of cyclophosphamide works to reduce these side effects, while also preventing GvHD. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for transplant.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. This study is being done to study whether treating PTLD with a combination of the drugs tafasitamab and rituximab is more effective than rituximab alone - the current standard of care treatment for this disease.

In this study, we want to learn more about the impact on progression-free survival (PFS) for patients with multiple myeloma when taking a combination of four drugs. The four drugs in this study are lenalidomide, ixazomib, dexamethasone, and daratumumab.

Have you been listed for kidney transplant at UNC? If so, you may be able to take part in a research study to help us learn how the process of waiting for a kidney transplant impacts you.

The purpose of this study is to learn more about the safety of the study drugs (venetoclax and azacitidine) and how well they work compared to Best Supportive Care in patients with AML after stem cell transplant.

Do you have severe sickle cell disease? If so, you may be eligible to participate in a research study that is looking at the safety and effectiveness of using your own modified stem cells as possible treatment.

Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).

Do you have multiple myeloma? Have you had a stem cell transplant? If so, you may be able to take part in a research study looking at the effectiveness of giving a drug called daratumumab, along with lenalidomide, after a stem cell transplant to patients with multiple myeloma.